What is GenTarget?
GenTarget operates at the intersection of advanced molecular biology and commercial research support, specializing in the development of high-quality lentivirus products. The company provides a comprehensive suite of tools, including CRISPR gene editing solutions and customized stable cell lines, which are essential for modern genetic engineering workflows. By catering to the rigorous demands of the research and development sector, GenTarget has established itself as a critical infrastructure provider for laboratories focused on cellular biology and therapeutic discovery. Its strategic location in San Diego places it at the heart of a global biotech hub, facilitating close collaboration with academic institutions and pharmaceutical innovators alike.
How much funding has GenTarget raised?
GenTarget has raised a total of $16K across 1 funding round:
Debt
$16K
Debt (2021): $16K with participation from PPP
Key Investors in GenTarget
PPP
Public-Private Partnership
What's next for GenTarget?
With the recent influx of capital, GenTarget is well-positioned to scale its operational capacity and expand its product portfolio. The company is expected to prioritize the enhancement of its CRISPR-based toolsets and the automation of its stable cell line production, addressing the growing demand for high-throughput genetic screening. As the firm navigates its current growth stage, the focus will likely shift toward optimizing supply chain efficiencies and broadening its international distribution network. This strategic roadmap is designed to capitalize on the increasing global reliance on viral vector technologies, ensuring that GenTarget remains a preferred partner for researchers pushing the boundaries of genomic medicine and synthetic biology.
See full GenTarget company page
